Physician profile
Christopher D Walker
NPI 1962881417
$660.23
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.18 · 2020: $31.21 · 2021: $31.50 · 2022: $15.65 · 2023: $159 · 2024: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $516.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $210.34 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $91.58 | 2024 | Lokelma |
| Pfizer INC. | $84.07 | 2024 | |
| Paratek Pharmaceuticals, INC. | $80.48 | 2023-2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $70.02 | 2019-2024 | Zerbaxa, Dificid, Recarbrio |
| E.R. Squibb & Sons, L.L.C. | $39.52 | 2020-2021 | |
| Inari Medical, INC. | $27.62 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $17.76 | 2023 | Gattex |
| Abbvie INC. | $15.65 | 2022 | |
| Mylan Specialty L.P. | $11.80 | 2020 | |
| Galderma Laboratories, L.P. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.